(WASHINGTON) — Five-year survival data published online in Blood, the Journal of the American Society of Hematology (ASH), suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies. This multinational Phase II study examines brentuximab vedotin (BV) in patients with Hodgkin lymphoma who relapsed after stem cell…